Anzeige
❌
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: 900964 | ISIN: US64125C1099 | Ticker-Symbol: NB3
Tradegate
21.07.25 | 18:50
112,10 Euro
-0,75 % -0,85
Branche
Biotechnologie
Aktienmarkt
NASDAQ Biotech
S&P MidCap 400
1-Jahres-Chart
NEUROCRINE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
NEUROCRINE BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
112,30114,5509:04
112,30114,5509:04

Aktuelle News zur NEUROCRINE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoTruist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential5Investing.com
15.07.NBIX: Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients335AFX NewsWASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) shared new results from a one-year clinical study at the Endocrine Society's 2025 Annual Meeting in San Francisco. The study looked...
► Artikel lesen
14.07.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual ...154PR NewswireAdult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductions ...
► Artikel lesen
14.07.Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025304AFX NewsWASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) Monday reported new positive data from the Phase 3 CAHtalyst Adult study of Crenessity in adults with classic congenital adrenal hyperplasia...
► Artikel lesen
14.07.Neurocrine reports positive results from Crenessity trial1Seeking Alpha
NEUROCRINE BIOSCIENCES Aktie jetzt für 0€ handeln
14.07.Neurocrine reports positive one-year data for CAH treatment1Investing.com
14.07.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY (crinecerfont) in Adult Patients, at ENDO 202569PR NewswireOne-year data from CAHtalyst Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital...
► Artikel lesen
10.07.Goldman Sachs initiates Neurocrine Bio. stock with Buy rating on growth outlook8Investing.com
09.07.A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts12Benzinga.com
30.06.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist96PR NewswireSAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study...
► Artikel lesen
20.06.Neurocrine berichtet über Verbesserungen der Lebensqualität bei älteren Erwachsenen, die INGREZZA nutzen5Investing.com Deutsch
20.06.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive ...152PR NewswireData Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings...
► Artikel lesen
09.06.Neurocrine Biosciences names new Chief Information Officer2Investing.com
09.06.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer285PR NewswireSAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025....
► Artikel lesen
04.06.Guggenheim maintains buy rating on Neurocrine Bio stock amid growth prospects4Investing.com
04.06.Guggenheim behält Kaufempfehlung für Neurocrine Bio-Aktie aufgrund von Wachstumsaussichten bei6Investing.com Deutsch
03.06.Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568142GlobeNewswire (Europe)Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first...
► Artikel lesen
02.06.Analyst Expectations For Neurocrine Biosciences' Future1Benzinga.com
02.06.Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data347AFX NewsWASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Monday announced data from the Phase 4 KINECT-PRO open-label study, evaluating patient-reported outcomes on the use of INGREZZA capsules...
► Artikel lesen
28.05.Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025152PR NewswireSAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia...
► Artikel lesen
1 2 3 4 5 Weiter >>
128 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1